Literature DB >> 11176938

Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability.

N De Stefano1, S Narayanan, G S Francis, R Arnaoutelis, M C Tartaglia, J P Antel, P M Matthews, D L Arnold.   

Abstract

OBJECTIVE: To assess axonal damage and its contribution to disability at different stages of multiple sclerosis (MS).
BACKGROUND: Recent in vivo imaging and in situ pathologic studies have demonstrated that substantial axonal damage accompanies the inflammatory lesions of MS. However, the relation of axonal damage to the duration of MS and its contribution to disability at different stages of the disease remain poorly defined.
DESIGN: We performed proton magnetic resonance spectroscopic imaging in 88 patients with a wide range of clinical disability and disease duration to measure N-acetylaspartate (NAA, an index of axonal integrity) relative to creatine (Cr) in a large central brain volume that included mostly normal-appearing white matter on magnetic resonance imaging.
RESULTS: We observed that the NAA/Cr values were abnormally low in the early stages of MS, even before significant disability (measured using the Expanded Disability Status Scale [EDSS]) was evident clinically, and declined more rapidly with respect to EDSS at lower than at higher EDSS scores (P<.001). The correlation of NAA/Cr values with EDSS score was significantly (P<.03) stronger in patients with mild disability (EDSS score <5, Spearman rank order correlation = -0.54, P<.001) than in patients with more severe disability (EDSS score >/=5, Spearman rank order correlation = -0.1, P<.9). When similar analyses were performed in patients with MS grouped for duration of disease, the subgroup with early disease duration (<5 years) also showed central brain NAA/Cr resonance intensity ratios significantly lower than healthy controls (P<.001).
CONCLUSION: Cerebral axonal damage begins and contributes to disability from the earliest stages of the disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11176938     DOI: 10.1001/archneur.58.1.65

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  121 in total

Review 1.  Clinical trials and clinical practice in multiple sclerosis: conventional and emerging magnetic resonance imaging technologies.

Authors:  Massimo Filippi; Maria A Rocca; Marco Rovaris
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 5.081

Review 2.  The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.

Authors:  Kedar R Mahajan; Daniel Ontaneda
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

3.  Simple and complex movement-associated functional MRI changes in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis.

Authors:  Massimo Filippi; Maria A Rocca; Domenico M Mezzapesa; Angelo Ghezzi; Andrea Falini; Vittorio Martinelli; Giuseppe Scotti; Giancarlo Comi
Journal:  Hum Brain Mapp       Date:  2004-02       Impact factor: 5.038

4.  Compensatory cortical activation observed by fMRI during a cognitive task at the earliest stage of MS.

Authors:  Bertrand Audoin; Danielle Ibarrola; Jean-Philippe Ranjeva; Sylviane Confort-Gouny; Irina Malikova; André Ali-Chérif; Jean Pelletier; Patrick Cozzone
Journal:  Hum Brain Mapp       Date:  2003-10       Impact factor: 5.038

5.  Neural stem/progenitor cells express costimulatory molecules that are differentially regulated by inflammatory and apoptotic stimuli.

Authors:  Jaime Imitola; Manuel Comabella; Anil K Chandraker; Fernando Dangond; Mohamed H Sayegh; Evan Y Snyder; Samia J Khoury
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

Review 6.  Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Prog Neurobiol       Date:  2010-10-12       Impact factor: 11.685

7.  Twelve-year monitoring of a patient with megalencephalic leukoencephalopathy with subcortical cysts.

Authors:  Francesca Rossi; Marco Battaglini; Maria Laura Stromillo; Antonio Giorgio; Antonio Federico; Nicola De Stefano
Journal:  Neurol Sci       Date:  2014-03-02       Impact factor: 3.307

8.  Cognitive impairment in probable multiple sclerosis.

Authors:  A Achiron; Y Barak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

9.  Prognostic value of high-field proton magnetic resonance spectroscopy in patients presenting with clinically isolated syndromes suggestive of multiple sclerosis.

Authors:  Mike P Wattjes; Michael Harzheim; Götz G Lutterbey; Manuela Bogdanow; Stephan Schmidt; Hans H Schild; Frank Träber
Journal:  Neuroradiology       Date:  2007-11-03       Impact factor: 2.804

10.  Brain metabolite profiles of T1-hypointense lesions in relapsing-remitting multiple sclerosis.

Authors:  Belinda S Y Li; Juleiga Regal; Brian J Soher; Lois J Mannon; Robert I Grossman; Oded Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2003-01       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.